What does an elevated fecal calprotectin indicate?

What Does an Elevated Fecal Calprotectin Indicate?

An elevated fecal calprotectin indicates active intestinal inflammation, most commonly from inflammatory bowel disease (IBD), but it is a non-specific marker that can be elevated in any condition causing neutrophilic infiltration of the gastrointestinal tract.

Primary Clinical Significance

Fecal calprotectin is a calcium- and zinc-binding protein released by neutrophils that migrate into gastrointestinal tissue during inflammation 1, 2. When elevated, it serves as a surrogate marker of mucosal inflammation with high sensitivity but limited specificity for the underlying cause 3.

Key Clinical Applications

Distinguishing IBD from Functional Disorders

The most established use is differentiating inflammatory bowel disease from irritable bowel syndrome (IBS). Fecal calprotectin has excellent negative predictive value—normal levels effectively rule out IBD in symptomatic patients 4, 5. This makes it particularly valuable as a screening tool to avoid unnecessary colonoscopies in patients with functional symptoms.

Specific Cutoff Interpretations

The clinical interpretation depends heavily on the cutoff value and clinical context:

For Ulcerative Colitis:

• >150 mg/g with moderate-to-severe symptoms: Reliably indicates moderate-to-severe endoscopic inflammation, allowing treatment adjustment without immediate endoscopy 6
• >150 mg/g with mild symptoms: Warrants endoscopic assessment rather than empiric treatment changes, as the false positive rate reaches 15.5% 6
• <150 mg/g in symptomatic patients: Does NOT reliably exclude inflammation—false negative rates can reach 24.7% in high pretest probability scenarios 6

For Crohn's Disease:

• >150 mg/g with moderate-to-severe symptoms: Indicates active inflammation and supports treatment adjustment without routine endoscopy 7
• <150 mg/g in asymptomatic patients with recent endoscopic remission: Effectively rules out active inflammation 7
• >150 mg/g in asymptomatic patients: Requires endoscopic assessment before treatment changes 7

Monitoring Disease Activity

In established IBD, elevated calprotectin correlates with clinical disease activity and predicts relapse with >85% sensitivity and specificity 5. Persistently elevated levels in asymptomatic patients indicate subclinical inflammation that may warrant treatment intensification 7.

Important Caveats and Non-IBD Causes

Other Inflammatory Conditions

Elevated fecal calprotectin is NOT specific to IBD. It can be elevated in:

• Infectious gastroenteritis (bacterial, viral, parasitic)
• Colorectal cancer 1, 5
• NSAID-induced enteropathy 5
• Microscopic colitis
• Diverticulitis
• Post-surgical states: Particularly after esophagogastric surgery (56.7% have elevated levels) compared to colon surgery (24%) 8

Age Considerations

In adults ≥50 years, fecal calprotectin maintains high sensitivity (93.8%) for IBD, but the positive predictive value drops to only 12.8% due to higher rates of other pathology including colorectal cancer 9. In this age group, a positive fecal immunochemical test (FIT) outperforms elevated calprotectin for detecting organic pathology including cancer 9.

Special Populations

• Pediatric patients: Similar diagnostic performance as adults for IBD
• Post-surgical IBD patients: After intestinal resection, calprotectin <150 mg/g can rule out endoscopic recurrence in patients on prophylaxis, but sensitivity drops to 64% at this cutoff 7
• Cerebral palsy patients: May have elevated levels reflecting altered intestinal inflammatory activity unrelated to IBD 10

Clinical Decision Algorithm

When you encounter elevated fecal calprotectin:

1. Assess symptom severity and clinical context first

   • Moderate-to-severe GI symptoms + elevated calprotectin = likely active inflammation requiring treatment
   • Mild or no symptoms + elevated calprotectin = proceed to endoscopy before treatment changes

2. Consider pretest probability

   • Known IBD with symptoms: Elevated calprotectin supports active disease
   • New symptoms, no IBD diagnosis: Rule out infection, medications (NSAIDs), and age-appropriate cancer screening

3. Apply appropriate cutoffs

   • Use 150 mg/g as the primary threshold for clinical decision-making in IBD 6, 7
   • Lower cutoffs (50 mg/g) increase sensitivity but substantially increase false positives
   • Higher cutoffs (250 mg/g) increase specificity but miss more cases of active inflammation

4. Never rely on calprotectin alone in older adults (≥50 years) when cancer is a consideration—combine with FIT or proceed directly to colonoscopy 9

The critical pitfall is assuming normal calprotectin excludes inflammation in symptomatic patients with high pretest probability—false negative rates can exceed 25% in this scenario 6, 7.